Loading...
XJPX
4519
Market cap77bUSD
Jun 19, Last price  
7,550.00JPY
1D
-0.21%
1Q
-12.72%
Jan 2017
575.11%
Name

Chugai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4519 chart
P/E
32.08
P/S
10.61
EPS
235.34
Div Yield, %
3.30%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
11.27%
Revenues
1.26t
+7.46%
326,109,000,000344,808,000,000326,937,000,000428,947,000,000379,509,000,000373,516,000,000386,552,000,000423,652,000,000461,109,000,000498,839,000,000491,780,000,000534,199,000,000579,787,000,000686,184,000,000786,945,000,000999,758,000,0001,259,946,000,0001,111,367,000,0001,170,611,000,0001,257,941,000,000
Net income
434.01b
+12.06%
38,417,000,00040,060,000,00039,265,000,00056,634,000,00041,433,000,00035,234,000,00048,205,000,00050,895,000,00050,980,000,00061,125,000,00053,592,000,00072,713,000,00092,488,000,000157,560,000,000214,733,000,000302,995,000,000374,429,000,000325,472,000,000387,317,000,000434,012,000,000
CFO
389.45b
-12.99%
40,538,000,00060,364,000,00039,277,000,00066,461,000,00015,572,000,00069,593,000,00077,299,000,00053,521,000,00037,034,000,00062,918,000,00038,787,000,000107,623,000,000119,074,000,000206,641,000,000205,035,000,000279,626,000,000244,112,000,000409,925,000,000447,600,000,000389,451,000,000
Dividend
Jun 29, 202665 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Chugai Pharmaceutical Co., Ltd., along with its affiliated entities, is a global pharmaceutical company deeply involved in the discovery, development, production, marketing, and distribution of medicines. Its diverse product portfolio addresses a range of therapeutic areas. Key cancer treatments include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. For osteoporosis, it offers Actemra, Edirol, and Bonviva. Renal conditions are treated with products such as Mircera and Oxarol. Furthermore, its lineup for neurological and other diverse ailments features Hemlibra, CellCept, and Enspryng. The company maintains an active pipeline of investigational therapies across areas like oncology, musculoskeletal disorders, autoimmune diseases, kidney issues, neurological conditions, and other health concerns. Chugai benefits from strategic partnerships with the Roche Group and collaborates on research projects with academic institutions. Established in Tokyo, Japan, in 1925, Chugai Pharmaceutical Co., Ltd. functions as a subsidiary of Roche Holding Ltd.
URL
https://www.chugai-pharm.co.jp/
IPO date
Mar 03, 1956
Employees
7,771
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT